Brincidofovir - Chimerix

Drug Profile

Brincidofovir - Chimerix

Alternative Names: BCV; Cidofovir hexadecyloxypropyl ester; Cidofovir PIM conjugate; CMX-001; HDP-CDV; HDP-cidofovir; Hexadecyl-oxypropyl cidofovir - Chimerix

Latest Information Update: 20 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California, San Diego
  • Developer Centers for Disease Control and Prevention; Chimerix; National Institutes of Health (USA); University of Oxford
  • Class Antivirals; Phosphonic acids; Pyrimidinones; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections; Smallpox; Adenovirus infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Adenovirus infections; Cytomegalovirus infections; Smallpox
  • Phase II/III Viral infections
  • Research Monkeypox
  • No development reported Human polyomavirus infections
  • Discontinued Ebola virus infections

Most Recent Events

  • 07 Jun 2018 Brincidofovir - Chimerix receives Orphan Drug status for Smallpox in USA
  • 22 May 2018 Chimerix plans a phase II trial for Adenovirus infections in May 2018 , (NCT03532035)
  • 01 Mar 2018 Chimerix announces intention to submit MAA to EMA for Small Pox in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top